Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

BioPharma Dive

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

CommercialOncologyRead full story